
Bright Minds (DRUG) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Operating Income
-2.4M
Net Income
-3.8M
EPS (Diluted)
$-0.74
Balance Sheet Metrics
Total Assets
38.1M
Total Liabilities
484.2K
Shareholders Equity
37.6M
Debt to Equity
0.01
Cash Flow Metrics
Operating Cash Flow
-4.1M
Free Cash Flow
-2.5M
Revenue & Profitability Trend
Bright Minds Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 855.6K | 5.0M | 12.2M | 6.3M | 354.9K |
Selling, General & Administrative | 1.0M | 2.2M | 2.6M | 2.3M | 114.5K |
Other Operating Expenses | 143.0K | 186.7K | 243.1K | 181.7K | 5.5K |
Total Operating Expenses | 2.0M | 7.4M | 15.0M | 8.8M | 474.8K |
Operating Income | -2.0M | -7.4M | -15.0M | -8.8M | -474.8K |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 21.8K | 0 | 0 | - | - |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | -6.8K | 14.2K | 10.2K | 154.1K | -5.5K |
Pre-tax Income | -2.0M | -7.4M | -15.0M | -8.7M | -480.4K |
Income Tax | - | - | - | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -2.0M | -7.4M | -15.0M | -8.7M | -480.4K |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -2.0M | -7.3M | -15.0M | -8.9M | -474.8K |
EPS (Basic) | $-0.65 | $-1.98 | $-6.06 | $-4.82 | $-0.38 |
EPS (Diluted) | $-0.65 | $-1.98 | $-6.06 | $-4.82 | $-0.38 |
Basic Shares Outstanding | 3125121 | 5276872 | 3504485 | 2546110 | 1816793 |
Diluted Shares Outstanding | 3125121 | 5276872 | 3504485 | 2546110 | 1816793 |
Income Statement Trend
Bright Minds Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 4.1M | 6.7M | 11.6M | 19.8M | 799.9K |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 4.3M | 6.8M | 11.9M | 20.0M | 878.2K |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 138.9K | - | - |
Goodwill | - | - | 0 | 2.0K | 2.0K |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 85.3K | 66.4K | 138.9K | 2.0K | 2.0K |
Total Assets | 4.4M | 6.9M | 12.1M | 20.0M | 880.2K |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 295.5K | 182.3K | 1.2M | 596.6K | 138.4K |
Short-term Debt | 57.6K | 73.5K | 67.9K | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 383.3K | 280.9K | 1.5M | 638.6K | 150.9K |
Non-Current Liabilities | |||||
Long-term Debt | 28.7K | 0 | 72.0K | 0 | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 28.7K | 0 | 72.0K | 0 | 0 |
Total Liabilities | 412.0K | 280.9K | 1.5M | 638.6K | 150.9K |
Equity | |||||
Common Stock | 25.7M | 33.9M | 32.2M | 27.1M | 980.7K |
Retained Earnings | -24.9M | -31.5M | -24.2M | -9.2M | -559.1K |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 4.0M | 6.6M | 10.5M | 19.4M | 729.3K |
Key Metrics | |||||
Total Debt | 86.3K | 73.5K | 139.9K | 0 | 0 |
Working Capital | 4.0M | 6.5M | 10.5M | 19.4M | 727.3K |
Balance Sheet Composition
Bright Minds Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -2.0M | -7.4M | -15.0M | -8.7M | -480.4K |
Depreciation & Amortization | 53.2K | 72.4K | 6.0K | 0 | 0 |
Stock-Based Compensation | 608.9K | 1.2M | 875.1K | 880.6K | 161.3K |
Working Capital Changes | -9.6K | 118.8K | -43.5K | -110.1K | 0 |
Operating Cash Flow | -1.4M | -6.0M | -14.1M | -7.5M | -319.1K |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | - | - | - | - | - |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -65.1K | -86.1K | -7.2K | 0 | 0 |
Financing Cash Flow | 587.5K | 1.1M | 3.2M | 25.9M | 1.0M |
Free Cash Flow | -1.3M | -7.0M | -13.6M | -7.3M | -288.4K |
Net Change in Cash | -785.1K | -4.9M | -10.9M | 18.4M | 689.3K |
Cash Flow Trend
Bright Minds Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
0.28
Forward P/E
-6.21
Price to Book
5.44
PEG Ratio
0.00
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-30.79%
Return on Assets
-18.31%
Financial Health
Current Ratio
86.56
Debt to Equity
0.27
Beta
0.17
Per Share Data
EPS (TTM)
$-1.00
Book Value per Share
$7.32
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
drug | 246.0M | 0.28 | 5.44 | -30.79% | 0.00% | 0.27 |
Vertex | 102.8B | 27.77 | 5.83 | 22.77% | 31.86% | 8.89 |
Regeneron | 61.2B | 14.64 | 2.02 | 15.34% | 31.37% | 9.04 |
Atea Pharmaceuticals | 244.9M | -1.70 | 0.75 | -32.38% | 0.00% | 0.34 |
Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
ProQR Therapeutics | 241.2M | -7.25 | 3.54 | -79.47% | -231.45% | 25.17 |
Financial data is updated regularly. All figures are in the company's reporting currency.